Your browser doesn't support javascript.
loading
Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812].
Sharon, C E; Tortorello, G N; Ma, K L; Huang, A C; Xu, X; Giles, L R; McGettigan, S; Kreider, K; Schuchter, L M; Mathew, A J; Amaravadi, R K; Gimotty, P A; Miura, J T; Karakousis, G C; Mitchell, T C.
Afiliación
  • Sharon CE; Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia.
  • Tortorello GN; Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia.
  • Ma KL; Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia.
  • Huang AC; Department of Medicine and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Xu X; Department of Pathology and Laboratory Medicine.
  • Giles LR; Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia; Department of Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • McGettigan S; Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia; Department of Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Kreider K; Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia; Department of Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Schuchter LM; Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia; Department of Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Mathew AJ; Department of Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Amaravadi RK; Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia; Department of Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Gimotty PA; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
  • Miura JT; Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia; Department of Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Karakousis GC; Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia; Department of Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Mitchell TC; Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia; Department of Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Electronic address: tara.mitchell@pennmedicine.upenn.edu.
Ann Oncol ; 35(8): 756, 2024 Aug.
Article en En | MEDLINE | ID: mdl-38614876
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article